483 related articles for article (PubMed ID: 18342647)
1. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
Koltun W; Lucky AW; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
Contraception; 2008 Apr; 77(4):249-56. PubMed ID: 18342647
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment.
Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
J Drugs Dermatol; 2009 Sep; 8(9):837-44. PubMed ID: 19746676
[TBL] [Abstract][Full Text] [Related]
3. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.
Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
Obstet Gynecol; 2008 Oct; 112(4):773-81. PubMed ID: 18827119
[TBL] [Abstract][Full Text] [Related]
4. A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris.
Palli MB; Reyes-Habito CM; Lima XT; Kimball AB
J Drugs Dermatol; 2013 Jun; 12(6):633-7. PubMed ID: 23839178
[TBL] [Abstract][Full Text] [Related]
5. A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment.
Lucky AW; Koltun W; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
Cutis; 2008 Aug; 82(2):143-50. PubMed ID: 18792547
[TBL] [Abstract][Full Text] [Related]
6. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 μg plus drospirenone 3mg administered in a 24/4 regimen: a pooled analysis.
Koltun W; Maloney JM; Marr J; Kunz M
Eur J Obstet Gynecol Reprod Biol; 2011 Apr; 155(2):171-5. PubMed ID: 21288628
[TBL] [Abstract][Full Text] [Related]
7. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment.
Thorneycroft lH; Gollnick H; Schellschmidt I
Cutis; 2004 Aug; 74(2):123-30. PubMed ID: 15379365
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate.
Palombo-Kinne E; Schellschmidt I; Schumacher U; Gräser T
Contraception; 2009 Apr; 79(4):282-9. PubMed ID: 19272497
[TBL] [Abstract][Full Text] [Related]
9. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen.
Klipping C; Duijkers I; Trummer D; Marr J
Contraception; 2008 Jul; 78(1):16-25. PubMed ID: 18555813
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen.
Hernádi L; Marr J; Trummer D; De Leo V; Petraglia F
Contraception; 2009 Jul; 80(1):18-24. PubMed ID: 19501211
[TBL] [Abstract][Full Text] [Related]
11. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.
Anttila L; Kunz M; Marr J
Contraception; 2009 Nov; 80(5):445-51. PubMed ID: 19835718
[TBL] [Abstract][Full Text] [Related]
12. YAZ and the novel progestin drospirenone.
Mishell DR
J Reprod Med; 2008 Sep; 53(9 Suppl):721-8. PubMed ID: 18980044
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen.
Brucker C; Hedon B; The HS; Höschen K; Binder N; Christoph A
Contraception; 2010 Jun; 81(6):501-9. PubMed ID: 20472117
[TBL] [Abstract][Full Text] [Related]
14. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
Marr J; Gerlinger C; Kunz M
Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
[TBL] [Abstract][Full Text] [Related]
15. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.
van Vloten WA; van Haselen CW; van Zuuren EJ; Gerlinger C; Heithecker R
Cutis; 2002 Apr; 69(4 Suppl):2-15. PubMed ID: 12096825
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial.
Plewig G; Cunliffe WJ; Binder N; Höschen K
Contraception; 2009 Jul; 80(1):25-33. PubMed ID: 19501212
[TBL] [Abstract][Full Text] [Related]
17. Folate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: a randomized, double-blind, active-controlled, parallel-group, US-based multicenter study.
Bart S; Marr J; Diefenbach K; Trummer D; Sampson-Landers C
Contraception; 2012 Jan; 85(1):42-50. PubMed ID: 22067790
[TBL] [Abstract][Full Text] [Related]
18. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
Pearlstein TB; Bachmann GA; Zacur HA; Yonkers KA
Contraception; 2005 Dec; 72(6):414-21. PubMed ID: 16307962
[TBL] [Abstract][Full Text] [Related]
19. Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone.
Blode H; Schürmann R; Benda N
Contraception; 2008 Mar; 77(3):171-6. PubMed ID: 18279686
[TBL] [Abstract][Full Text] [Related]
20. Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: II. Clinical effects.
Zimmerman Y; Foidart JM; Pintiaux A; Minon JM; Fauser BC; Cobey K; Coelingh Bennink HJ
Contraception; 2015 Feb; 91(2):134-42. PubMed ID: 25496917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
